Non-Small Cell Lung Cancer Therapeutics Market: Snapshot
Non-small cell lung cancer (NSCLC) is the one of the commonest form of lung cancers. It is the most feared too. This is because it metastasizes into the bones and other tissues, making it tough to diagnose and treat it. In fact, almost 90% of all lung cancer cases are non-small cell lung cancer. Drugs meant to treat such a type of cancer range from regular regimens to targeted therapies. They are formulated leveraging simple chemistries to advanced complex proteins. The global market for non-small cell lung cancer therapeutics has seen robust growth due to the strong awareness among people about it. Another factor majorly contributing to the market is favorable government initiatives. Further, rapid approvals for drugs for non-small cell lung cancer by regulatory bodies and generous monetary assistance for research has also filliped the market.
Despite the efficacy of targeted therapies and the uncovering of numerous molecular targets, the development of most drugs is in an early-stage pipeline. This, coupled with resistance to targeted therapies, is a major cause of worry in the non-small cell lung cancer therapeutics market.
The global non-small cell lung cancer therapeutics market was worth US$4.9 bn in 2014. Expanding at a CAGR of 12.1% from 2015 to 2023, it is slated to achieve a value of US$15.1 bn in 2023. The global non-small cell lung cancer therapeutics market is a fragmented with robust competition among the existing players that are both generic and branded companies. Some of the prominent names operating in the market are Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Inc., AstraZeneca plc, and Novartis AG.
Burgeoning Population to Propel Market in Asia Pacific
The global market for non-small cell lung cancer therapeutics comprises five key regions: North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America leads with maximum share in market on account of the presence of a superior healthcare infrastructure and strong support by the U.S. federal government. In terms of growth rate, however, Asia Pacific is predicted to outshine all other regions owing to the burgeoning population, growing awareness about non-small cell lung cancer, increasing number of government projects pertaining to lung cancer, and ongoing efforts for timely intervention.
Effectiveness of Angiogenesis Inhibitor Drives Growth
The global market for non-small cell lung cancer therapeutics market can be segmented on the basis of drugs into EGFR inhibitor, angiogenesis inhibitor, microtubule stabilizer, kinase inhibitor, folate antimetabolites, and PD-1/PD-L1 inhibitor. At present angiogenesis inhibitor, also known as anti-angiogenics that thwart formation of new blood vessels, dominates the market. Going forward too, it is likely to retain its leading position because of the strong demand for this efficacious, targeted therapy in the crucial Europe, Japan, and the U.S. markets. Avastin, a type of angiogenesis inhibitor, is predicted to see maximum uptake. Exhibiting a CAGR of 1.8% from 2015 to 2023, the angiogenesis inhibitor segment is predicted to attain a market value of US$ 2,020.4 mn by 2023.
The folate antimetabolites segment trails the angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments come in third and fourth positions in terms of market share. The PD-1/PD-L1 inhibitor will likely outpace all other segments vis-à-vis growth in the upcoming years due to the effectiveness of the treatment, which has been corroborated by clinical data that shows double survival rate. Unveiling of new targeted therapies with more surveillance rate could, however, hobble the growth in the market.
1.1. Report Description
1.2. Research Methodology
1.3. Market Segmentation
2. Executive Summary
2.1. Market Snapshot
2.2. Comparative Analysis: Non-Small Cell Lung Cancer Market, by Geography, 2014 & 2023 (Value %)
3. Non-Small Cell Lung Cancer Market Overview
3.2. Treatment Guidelines and Disease Management
3.3. Companion Diagnostics: Overview
3.4. Regulatory Scenario
3.5. Market Dynamics
3.6. Event Impact Analysis, 2013 - 2023
3.7. Market Attractiveness Analysis of Global Non-Small Cell Lung Cancer Market, by Geography, 2014
3.8. Competitive Landscape
3.8.1. Market Share Analysis of Key Players, 2014 (Value %)
4. Market Segmentation – By Drug
4.2. Global Non-Small Cell Lung Cancer Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
4.2.1. Global Angiogenesis Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.2. Global EGFR Blockers Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.3. Global Kinase Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.4. Global Microtubule Stabilizer Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.5. Global Folate Antimetabolites Market Revenue, 2013–2023 (US$ Mn) and Analysis
4.2.6. Global PD-1/PD-L1 Inhibitor Market Revenue, 2013–2023 (US$ Mn) and Analysis
5. Pipeline Analysis
5.2. Late Stage (Phase III)
5.2.1. Avelumab - Pfizer, Inc.
5.2.2. MPDL3280A - Roche
5.2.3. MEDI4736 - AstraZeneca
5.2.4. Abemaciclib – Eli Lilly and Company
5.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)
6. Market Segmentation – By Geography
6.2. Global Non-Small Cell Lung Cancer Market Revenue, by Region, 2013–2023 (US$ Mn)
6.3. North America Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
6.3.1. U.S. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.3.2. Canada Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.4. Europe Non-Small Cell Lung Cancer Market – Revenue, by Country, 2013–2023 (US$ Mn)
6.4.1. U.K. Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.4.2. Germany Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.4.3. Rest of Europe Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.5. Asia Pacific Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
6.5.1. Japan Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.5.2. China Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.5.3. Rest of APAC Non-Small Cell Lung Cancer Market Revenue, 2013–2023, (US$ Mn)
6.6. Rest of the World Non-Small Cell Lung Cancer Market Revenue, by Country, 2013–2023 (US$ Mn)
7.1. Recommendation 1: Research and Development Initiatives to Penetrate the Market
7.2. Recommendation 2: Investment in Emerging Economy
8. Company Profiles
8.1. Astra Zeneca PLC
8.2. Boehringer Ingelheim
8.3. Bristol-Myers Squibb
8.4. Celgene Corporation
8.5. GlaxoSmithKline PLC
8.6. Eli Lilly & Co.
8.7. Pfizer, Inc.
8.8. Genentech, Inc. (a Roche company)
8.9. Sun Pharmaceutical Industries Ltd.
Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period.
In this research report, the global NSCLC therapeutics market has been studied with a microscopic view. It aims at presenting a detailed market assessment on the basis of its past as well as current performance. The latest trends and growth opportunities within this market have been examined in-depth to determine its future status in this study.
Non-Small Cell Lung Cancer Therapeutics Market: Trends and Opportunities
Being the most common type of lung cancer, NSCLC has a large pool of patients suffering from it. Hitherto, angiogenesis inhibitor has been the most successful therapy for NSCLC. The high demand for Avastin in the U.S. and in several European countries is likely to maintain the position of angiogenesis inhibitor as the key treatment for NSCLC in the years to come.
Folate antimetabolites, EGFR inhibitors, and microtubule stabilizers are also expected to gain momentum in the global market over the next few years. In addition, the approval of late-stage pipeline products, such as necitumumab and onartuzumab, are likely to create new revenue streams for drugmakers in the near future.
Non-small Cell Lung Cancer Therapeutics Market: Geographical Analysis
On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years.
On the other hand, Asia Pacific is anticipated to offer the most promising opportunities for growth in the near future. The increasing incidence of NSCLC, coupled with unmet medical needs, is likely to make way for the adoption of NSCLC therapeutics at a higher rate. The rise in government initiatives to increase awareness regarding NSCLC among consumers in this region is also projected to propel the Asia Pacific market for NSCLC therapeutics substantially over the next few years.
Companies Mentioned in the Research Report
Owing to the presence of a large pool of players, the global market for non-small cell lung cancer therapeutics demonstrates a highly competitive and fragmented landscape. Genentech Inc., GlaxoSmithKline PLC, Pfizer Inc., Astra Zeneca PLC, Celgene Corp., Eli Lilly & Co., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the key players in this market across the world.
Key Segments of Non-Small Cell Lung Cancer Therapeutics Market
By Drug Class
- Angiogenesis Inhibitor
- Avastin (bevacizumab)
- Cyramza (Ramucirumab)
- Epidermal Growth Factor Receptor Blocker
- Tarceva (erlotinib)
- Gilotrif (afatinib)
- Iressa (gefitinib)
- Kinase Inhibitor
- Xalkori (crizotinib)
- Zykadia (ceritinib)
- Microtubule Stabilizer
- Abraxane (paclitaxel protein bound)
- Folate Antimetabolites
- Alimta (pemetrexed)
- PD-1/ PD-L1 Inhibitor
- Opdivo (nivolumab)
- Keytruda (pembrolizumab)
- Early Stage (Phase I and II)
- Late Stage (Phase III)
- Avelumab - Pfizer Inc.
- MPDL3280A - Roche
- MEDI4736 - AstraZeneca
- Abemaciclib - Eli Lilly and Company
Major regions analyzed under this research report are:
- North America
- Asia Pacific
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments